Nuclear factor erythroid 2-related factor 2 deficiency results in amplification of the liver fat-lowering effect of estrogen

Wenjuan Rui, Yuhong Zou, Joonyong Lee, Shashank Manohar Nambiar, Jingmei Lin, Linjie Zhang, Yan Yang, Guoli Dai

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) regulates multiple biologic processes, including hepatic lipid metabolism. Estrogen exerts actions affecting energy homeostasis, including a liver fat-lowering effect. Increasing evidence indicates the crosstalk between these two molecules. The aim of this study was to evaluate whether Nrf2 modulates estrogen signaling in hepatic lipid metabolism. Nonalcoholic fatty liver disease (NAFLD) was induced in wild-type and Nrf2-null mice fed a high-fat diet and the liver fat-lowering effect of exogenous estrogen was subsequently assessed.Wefound that exogenous estrogen eliminated 49%and 90%of hepatic triglycerides in wild-type and Nrf2-null mice with NAFLD, respectively. This observation demonstrates that Nrf2 signaling is antagonistic to estrogen signaling in hepatic fat metabolism; thus, Nrf2 absence results in striking amplification of the liver fat-lowering effect of estrogen. In addition, we found the association of trefoil factor 3 and fatty acid binding protein 5 with the liver fat-lowering effect of estrogen. In summary, we identified Nrf2 as a novel and potent inhibitor of estrogen signaling in hepatic lipid metabolism. Our finding may provide a potential strategy to treat NAFLD by dually targeting Nrf2 and estrogen signaling.

Original languageEnglish (US)
Pages (from-to)14-21
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume358
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Estrogens
Fats
Liver
Lipid Metabolism
NF-E2 Transcription Factor
Fatty Acid-Binding Proteins
High Fat Diet
Triglycerides
Homeostasis
Non-alcoholic Fatty Liver Disease

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Medicine
  • Pharmacology

Cite this

Nuclear factor erythroid 2-related factor 2 deficiency results in amplification of the liver fat-lowering effect of estrogen. / Rui, Wenjuan; Zou, Yuhong; Lee, Joonyong; Nambiar, Shashank Manohar; Lin, Jingmei; Zhang, Linjie; Yang, Yan; Dai, Guoli.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 358, No. 1, 01.07.2016, p. 14-21.

Research output: Contribution to journalArticle

Rui, Wenjuan ; Zou, Yuhong ; Lee, Joonyong ; Nambiar, Shashank Manohar ; Lin, Jingmei ; Zhang, Linjie ; Yang, Yan ; Dai, Guoli. / Nuclear factor erythroid 2-related factor 2 deficiency results in amplification of the liver fat-lowering effect of estrogen. In: Journal of Pharmacology and Experimental Therapeutics. 2016 ; Vol. 358, No. 1. pp. 14-21.
@article{bf580743e36f4d37ab8f60a1fd5b940c,
title = "Nuclear factor erythroid 2-related factor 2 deficiency results in amplification of the liver fat-lowering effect of estrogen",
abstract = "Transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) regulates multiple biologic processes, including hepatic lipid metabolism. Estrogen exerts actions affecting energy homeostasis, including a liver fat-lowering effect. Increasing evidence indicates the crosstalk between these two molecules. The aim of this study was to evaluate whether Nrf2 modulates estrogen signaling in hepatic lipid metabolism. Nonalcoholic fatty liver disease (NAFLD) was induced in wild-type and Nrf2-null mice fed a high-fat diet and the liver fat-lowering effect of exogenous estrogen was subsequently assessed.Wefound that exogenous estrogen eliminated 49{\%}and 90{\%}of hepatic triglycerides in wild-type and Nrf2-null mice with NAFLD, respectively. This observation demonstrates that Nrf2 signaling is antagonistic to estrogen signaling in hepatic fat metabolism; thus, Nrf2 absence results in striking amplification of the liver fat-lowering effect of estrogen. In addition, we found the association of trefoil factor 3 and fatty acid binding protein 5 with the liver fat-lowering effect of estrogen. In summary, we identified Nrf2 as a novel and potent inhibitor of estrogen signaling in hepatic lipid metabolism. Our finding may provide a potential strategy to treat NAFLD by dually targeting Nrf2 and estrogen signaling.",
author = "Wenjuan Rui and Yuhong Zou and Joonyong Lee and Nambiar, {Shashank Manohar} and Jingmei Lin and Linjie Zhang and Yan Yang and Guoli Dai",
year = "2016",
month = "7",
day = "1",
doi = "10.1124/jpet.115.231316",
language = "English (US)",
volume = "358",
pages = "14--21",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Nuclear factor erythroid 2-related factor 2 deficiency results in amplification of the liver fat-lowering effect of estrogen

AU - Rui, Wenjuan

AU - Zou, Yuhong

AU - Lee, Joonyong

AU - Nambiar, Shashank Manohar

AU - Lin, Jingmei

AU - Zhang, Linjie

AU - Yang, Yan

AU - Dai, Guoli

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) regulates multiple biologic processes, including hepatic lipid metabolism. Estrogen exerts actions affecting energy homeostasis, including a liver fat-lowering effect. Increasing evidence indicates the crosstalk between these two molecules. The aim of this study was to evaluate whether Nrf2 modulates estrogen signaling in hepatic lipid metabolism. Nonalcoholic fatty liver disease (NAFLD) was induced in wild-type and Nrf2-null mice fed a high-fat diet and the liver fat-lowering effect of exogenous estrogen was subsequently assessed.Wefound that exogenous estrogen eliminated 49%and 90%of hepatic triglycerides in wild-type and Nrf2-null mice with NAFLD, respectively. This observation demonstrates that Nrf2 signaling is antagonistic to estrogen signaling in hepatic fat metabolism; thus, Nrf2 absence results in striking amplification of the liver fat-lowering effect of estrogen. In addition, we found the association of trefoil factor 3 and fatty acid binding protein 5 with the liver fat-lowering effect of estrogen. In summary, we identified Nrf2 as a novel and potent inhibitor of estrogen signaling in hepatic lipid metabolism. Our finding may provide a potential strategy to treat NAFLD by dually targeting Nrf2 and estrogen signaling.

AB - Transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) regulates multiple biologic processes, including hepatic lipid metabolism. Estrogen exerts actions affecting energy homeostasis, including a liver fat-lowering effect. Increasing evidence indicates the crosstalk between these two molecules. The aim of this study was to evaluate whether Nrf2 modulates estrogen signaling in hepatic lipid metabolism. Nonalcoholic fatty liver disease (NAFLD) was induced in wild-type and Nrf2-null mice fed a high-fat diet and the liver fat-lowering effect of exogenous estrogen was subsequently assessed.Wefound that exogenous estrogen eliminated 49%and 90%of hepatic triglycerides in wild-type and Nrf2-null mice with NAFLD, respectively. This observation demonstrates that Nrf2 signaling is antagonistic to estrogen signaling in hepatic fat metabolism; thus, Nrf2 absence results in striking amplification of the liver fat-lowering effect of estrogen. In addition, we found the association of trefoil factor 3 and fatty acid binding protein 5 with the liver fat-lowering effect of estrogen. In summary, we identified Nrf2 as a novel and potent inhibitor of estrogen signaling in hepatic lipid metabolism. Our finding may provide a potential strategy to treat NAFLD by dually targeting Nrf2 and estrogen signaling.

UR - http://www.scopus.com/inward/record.url?scp=84976407441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976407441&partnerID=8YFLogxK

U2 - 10.1124/jpet.115.231316

DO - 10.1124/jpet.115.231316

M3 - Article

C2 - 27189962

AN - SCOPUS:84976407441

VL - 358

SP - 14

EP - 21

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -